Application of Translational Science to Clinical Development - Genomic Biomarkers for Pharmaceutical Development - page 19

[22] Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Geitinib plus best sup-
portive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from
a randomised, placebo controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet
2005;366:1527-37.
[23] Chang A, Parikh P, Thongprasert S, et al. Geitinib (IRESSA) in patients of Asian origin with refractory
advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55.
[24] Hirsch FR, Varella-Garcia M, Bunn Jr PA, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predic-
tors of outcome with geitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer.
J Clin Oncol 2006;24:5034-42.
[25] Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, et al. Eficacy of geitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a
randomized trial. JAMA 2003;290:2149-58.
[26] Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Geitinib versus docetaxel in previously treated
non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 2008;372:1809-18.
[27] Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome
with geitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase
III INTEREST trial. J Clin Oncol 2010;28:744-52.
[28] Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geitinib or carboplatin-paclitaxel in pulmo-
nary adenocarcinoma. N Engl J Med 2009;361:947-57.
[29] Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and
final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carbopl-
atin / paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol
29; 2866-74.
[30] http: // www.iressa.com / _mshost5259502 / content / 6906430 / July2009.pdf
[31] Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, North-East Japan Study Group.
Geitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
[32] Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, West Japan Oncology Group. Geitinib
versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epi-
dermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. Lancet Oncol
2010;11:121-8.
[33] Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Spanish Lung Cancer Group in collabora-
tion with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib
versus standard chemotherapy as irst-line treatment for European patients with advanced EGFR mutation-
positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised Phase III trial. Lancet
Oncol 2012;13:239-46.
[34] Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as irst-line treatment
for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a
multicenter, open-label, randomised, Phase III study. Lancet Oncol 2011;12:735-42.
[35] Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and
branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
[36] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepati-
tis C treatment-induced viral clearance. Nature 2009;461:399-401.
[37] Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of
IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet
2009;41:1105-9.
[38] Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response
to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
[39] Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Swiss Hepatitis C Cohort Study; Swiss HIV
Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a
genome-wide association study. Gastroenterology 2010;138:1338-45.
[40] Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous
clearance of hepatitis C virus. Nature 2009;461:798-801.
[41] Theoilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha / beta) in immunity and autoim-
munity. Annu Rev Immunol 2005;23:307-36.